Literature DB >> 25510899

The TLR2 agonist in polysaccharide-K is a structurally distinct lipid which acts synergistically with the protein-bound β-glucan.

Kenneth Quayle1, Catherine Coy, Leanna Standish, Hailing Lu.   

Abstract

Protein-bound polysaccharide-K (Krestin; PSK) is a hot-water extract of Trametes versicolor with immune stimulatory activity. It has been used for the past 30 years and has demonstrated anti-tumor efficacy in multiple types of cancer. The ability of PSK to activate dendritic cells and T cells is dependent on its ability to stimulate Toll-like receptor 2 (TLR2), yet it remains unknown which structural component within PSK activates TLR2. The purpose of this study was to identify the TLR2 agonist within PSK and understand its role in the overall mechanism of PSK's immunogenic activity. TLR2 activity was eliminated by treatment with lipoprotein lipase but not by trypsin or lyticase. Rapid centrifugation of PSK can separate the fraction with TLR2 agonist activity from the soluble β-glucan fraction. To study the potential interaction between the β-glucan component and the lipid component, we labeled the soluble β-glucan with fluorescein. Uptake of the labeled β-glucan by J774A macrophages and JAWSII dendritic cells was inhibited by anti-Dectin-1 antibody but not by anti-TLR2 antibody, confirming that Dectin-1 is the receptor for β-glucan. Interestingly, pre-treatment of JAWSII cells with the TLR2-active lipid fraction significantly enhanced the uptake of the soluble β-glucan, indicating the synergy between the TLR2 agonist component and the β-glucan component. Altogether, these results present evidence that PSK has two active components-the well-characterized protein-bound β-glucan and a previously unreported lipid-which work synergistically via the Dectin-1 and TLR2 receptors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25510899     DOI: 10.1007/s11418-014-0879-z

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  43 in total

1.  The majority of in vitro macrophage activation exhibited by extracts of some immune enhancing botanicals is due to bacterial lipoproteins and lipopolysaccharides.

Authors:  Nirmal D Pugh; Hemlata Tamta; Premalatha Balachandran; Xiangmei Wu; J'Lynn Howell; Franck E Dayan; David S Pasco
Journal:  Int Immunopharmacol       Date:  2008-04-07       Impact factor: 4.932

2.  Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.

Authors:  Masahiko Shibata; Takeshi Nezu; Hisao Kanou; Yasuhiko Nagata; Tomo Kimura; Motoo Takekawa; Katsuyuki Ando; Masahiro Fukuzawa
Journal:  Cancer Invest       Date:  2002       Impact factor: 2.176

Review 3.  Fungal beta-glucans and mammalian immunity.

Authors:  Gordon D Brown; Siamon Gordon
Journal:  Immunity       Date:  2003-09       Impact factor: 31.745

Review 4.  Krestin (PSK).

Authors:  S Tsukagoshi; Y Hashimoto; G Fujii; H Kobayashi; K Nomoto; K Orita
Journal:  Cancer Treat Rev       Date:  1984-06       Impact factor: 12.111

5.  Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Authors:  M Toi; T Hattori; M Akagi; K Inokuchi; K Orita; K Sugimachi; K Dohi; Y Nomura; Y Monden; Y Hamada
Journal:  Cancer       Date:  1992-11-15       Impact factor: 6.860

6.  Variability in in vitro macrophage activation by commercially diverse bulk echinacea plant material is predominantly due to bacterial lipoproteins and lipopolysaccharides.

Authors:  Hemlata Tamta; Nirmal D Pugh; Premalatha Balachandran; Rita Moraes; Joko Sumiyanto; David S Pasco
Journal:  J Agric Food Chem       Date:  2008-11-26       Impact factor: 5.279

7.  Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Authors:  Abbi L Engel; Guan-Cheng Sun; Ekram Gad; Lauren R Rastetter; Katie Strobe; Yi Yang; Yushe Dang; Mary L Disis; Hailing Lu
Journal:  Immunobiology       Date:  2013-05-13       Impact factor: 3.144

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 10.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

View more
  8 in total

Review 1.  Modulation of Toll-like receptor signaling in innate immunity by natural products.

Authors:  Luxi Chen; Jianhua Yu
Journal:  Int Immunopharmacol       Date:  2016-02-15       Impact factor: 4.932

2.  Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation.

Authors:  Constance Mayslich; Philippe Alain Grange; Mathieu Castela; Anne Geneviève Marcelin; Vincent Calvez; Nicolas Dupin
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

3.  A Proinflammatory Effect of the β-Glucan from Pleurotus cornucopiae Mushroom on Macrophage Action.

Authors:  Ken-Ichiro Minato; Akihiro Ohara; Masashi Mizuno
Journal:  Mediators Inflamm       Date:  2017-05-15       Impact factor: 4.711

4.  Design and Immunological Evaluation of a Hybrid Peptide as a Potent TLR2 Agonist by Structure-Based Virtual Screening.

Authors:  Lulu Zhang; Xubiao Wei; Rijun Zhang; Paul E Mozdziak; Dayong Si; Baseer Ahmad; Qiang Cheng; Yucui Tong
Journal:  Front Cell Dev Biol       Date:  2021-02-11

5.  The Cordyceps militaris-Derived Polysaccharide CM1 Alleviates Atherosclerosis in LDLR(-/-) Mice by Improving Hyperlipidemia.

Authors:  Fan Yin; Ping Lin; Wen-Qian Yu; Nuo Shen; Yuan Li; Shou-Dong Guo
Journal:  Front Mol Biosci       Date:  2021-12-13

Review 6.  Trametes versicolor (Synn. Coriolus versicolor) Polysaccharides in Cancer Therapy: Targets and Efficacy.

Authors:  Solomon Habtemariam
Journal:  Biomedicines       Date:  2020-05-25

Review 7.  Medicinal mushrooms as an attractive new source of natural compounds for future cancer therapy.

Authors:  Artem Blagodatski; Margarita Yatsunskaya; Valeriia Mikhailova; Vladlena Tiasto; Alexander Kagansky; Vladimir L Katanaev
Journal:  Oncotarget       Date:  2018-06-26

8.  Differential Immune Activating, Anti-Inflammatory, and Regenerative Properties of the Aqueous, Ethanol, and Solid Fractions of a Medicinal Mushroom Blend.

Authors:  Renee Davis; Alex Taylor; Regan Nally; Kathleen F Benson; Paul Stamets; Gitte S Jensen
Journal:  J Inflamm Res       Date:  2020-02-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.